Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuZFZhonghua FuFYFan Yang

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds complete responses in large B-cell lymphoma after glofitamab bridging and CAR-T therapy, suggesting improved outcomes.

Key Points

  • The study aims to evaluate the effectiveness of glofitamab as a bridging therapy prior to CAR-T infusion in B-NHL patients.
  • Retrospective analysis of 9 patients with large B-cell lymphoma who received glofitamab as bridging therapy before CAR-T treatment.
  • Patients underwent leukapheresis for CAR-T manufacturing before receiving glofitamab.
  • Assessment included overall response rate and response duration following treatment.
  • Overall response rate of 100% (9/9) after first glofitamab cycle, with 2 complete responses reported.
  • Post-CAR-T follow-up showed 5 patients in remission after 3 months.
  • Median overall survival was 12.46 months, and median progression-free survival was 5.92 months.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8echttps://doi.org/10.1182/blood-2025-7259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  2. 2Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  3. 3Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations